Start-Up CEO: Making the Choices to Develop a Novel Medicine

The choices surrounding research investment and drug development are daunting for even the most experienced and successful biopharma executives. CEOs and other company leaders must consider a number of complex factors and market data to decide which therapeutic assets warrant investments, and their choices can drastically alter the future of a company.
An interactive panel at BIO 2017 provided attendees with a first-person perspective into how biopharma CEOs weight these factors. The panel of in